HLN.LSE Haleon PLC

Healthcare Biotechnology London Exchange
3.27 GBX
Close of Nov 3, 2026
310.50 433.60
Market cap
GBX 28.8B
P/E
18.2x
P/B
1.72x
ROE
9.3%
Dividend yield
2.26%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is HLN.LSE undervalued?

Graham number
Price3.27
Graham value2.78
Premium17.7%

HLN.LSE trades 17.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Haleon PLC fundamental analysis

No fundamental analysis for Haleon PLC yet.

Haleon PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.…

Full company profile